UK markets closed

Vifor Pharma AG (GNHAY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
36.840.00 (0.00%)
As of 09:36AM EST. Market open.

Vifor Pharma AG

Rechenstrasse 37
Sankt Gallen 9014
41 58 851 80 00

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees2,200

Key executives

NameTitlePayExercisedYear born
Mr. Alexandros SigalasActing CFO & Head of IT & Admin.N/AN/AN/A
Mr. Frederic ZwahlenHead of Technical OperationsN/AN/AN/A
Mr. Julien VignotHead of Investor Relations & TreasuryN/AN/AN/A
Dr. Oliver P. KronenbergGroup Gen. CounselN/AN/AN/A
Ms. Nathalie PonnierGlobal Head Corp. CommunicationsN/AN/AN/A
Mr. Michael PuriChief HR OfficerN/AN/A1969
Dr. Christoph SpringerChief Strategy OfficerN/AN/A1968
Dr. Thomas KasparHead of Global Quality ManagementN/AN/AN/A
Dr. Thierry TeilHead of Global Medical AffairsN/AN/AN/A
Ms. Carolina PonchioneHead of Exec. Search & Employer BrandingN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD).It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; and Veltassa for the treatment of hyperkalemia in CKD and chronic heart failure patients. Further, it develops Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of altitude on oxygen availability; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases;ANG-3777 for the treatment of transplant-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi and Zeria Pharmaceutical. The company was founded in 1872 and is headquartered in Sankt Gallen, Switzerland. As of August 9, 2022, Vifor Pharma AG operates as a subsidiary of CSL Behring AG.

Corporate governance

Vifor Pharma AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.